BriaCell Therapeutics Corp. (BCTX)
3.435
+0.02
(+0.73%)
USD |
NASDAQ |
Oct 23, 16:00
3.42
-0.02
(-0.44%)
After-Hours: 20:00
BriaCell Therapeutics Enterprise Value : 1.452M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.452M |
| October 22, 2026 | 1.271M |
| October 21, 2026 | 2.648M |
| October 20, 2026 | 1.633M |
| October 19, 2026 | 1.053M |
| October 16, 2026 | 1.198M |
| October 15, 2026 | 3.845M |
| October 14, 2026 | 3.301M |
| October 13, 2026 | 3.446M |
| October 12, 2026 | 4.606M |
| October 09, 2026 | 4.896M |
| October 08, 2026 | 4.968M |
| October 07, 2026 | 5.548M |
| October 06, 2026 | 5.694M |
| October 05, 2026 | 6.854M |
| October 02, 2026 | 5.838M |
| October 01, 2026 | 6.346M |
| September 30, 2026 | 7.579M |
| September 29, 2026 | 6.128M |
| September 28, 2026 | 6.672M |
| September 25, 2026 | 7.832M |
| September 24, 2026 | 7.579M |
| September 23, 2026 | 5.621M |
| September 22, 2026 | 6.201M |
| September 21, 2026 | 6.636M |
| Date | Value |
|---|---|
| September 18, 2026 | 7.071M |
| September 17, 2026 | 7.144M |
| September 16, 2026 | 2.358M |
| September 15, 2026 | 2.503M |
| September 14, 2026 | 2.358M |
| September 11, 2026 | 2.866M |
| September 10, 2026 | 2.648M |
| September 09, 2026 | 2.866M |
| September 08, 2026 | 2.467M |
| September 04, 2026 | 2.431M |
| September 03, 2026 | 2.141M |
| September 02, 2026 | 2.431M |
| September 01, 2026 | 2.866M |
| August 31, 2026 | 2.576M |
| August 28, 2026 | 3.591M |
| August 27, 2026 | 3.446M |
| August 26, 2026 | 5.766M |
| August 25, 2026 | 3.881M |
| August 24, 2026 | 1.633M |
| August 21, 2026 | 6.056M |
| August 20, 2026 | 5.041M |
| August 19, 2026 | 5.258M |
| August 18, 2026 | 2.141M |
| August 17, 2026 | 1.126M |
| August 14, 2026 | 1.488M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 24.76M |
| ProMIS Neurosciences, Inc. | 21.33M |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.237M |
| Total Expenses (Quarterly) | 7.164M |
| EPS Diluted (Quarterly) | -0.9881 |
| Earnings Yield | -355.5% |
| Normalized Earnings Yield | -362.85 |